Equities

Goldenwell Biotech Inc

GWLL:QBB

Goldenwell Biotech Inc

Actions
  • Price (USD)0.20
  • Today's Change0.00 / 0.00%
  • Shares traded2.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 28 2024 17:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Goldenwell Biotech, Inc. is in the development stage whose purpose is research and development, production and sales health cares and supplements products. The Company is offering its products under two categories: Polypeptide Freeze-dried Powder and Solid Tablets Products. The Company’s products are JI MAI-Bovine Cardiac Vascular Active Peptide, Double Proline AG- three-dimensional (3D) Active Collagen Peptide, Cartilage Peptide-Type II collagen peptide, Se Plus, and Sugar Master. Bovine cardiac vascular active peptide is a protein peptide of vascular homology (amino acid type and its sequence) which made from healthy and fresh bovine cardiac vascular tissues as raw materials. Its DPAG product is designed to be an easily absorbed bioactive collagen. Type II collagen peptide is prepared from Bovine or Pig Cartilage bones by hot water extraction. Its Sugar Master product is made utilizing low temperature extraction techniques to maximize the harvest of bio-actives of plant matter.

  • Revenue in USD (TTM)940.00
  • Net income in USD-137.11k
  • Incorporated2019
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NanoViricides Inc0.00-9.45m18.55m7.00--1.85-----0.7579-0.75790.000.71880.00----0.00-69.61-43.88-76.92-46.26------------0.00------3.43--16.23--
MEI Pharma Inc0.00-46.60m18.66m28.00--0.7499-----6.99-6.990.003.730.00----0.00-72.25-21.09-79.28-23.99-------72.23----0.00--33.7667.75155.84---49.68--
Mira Pharmaceuticals Inc0.00-11.24m18.70m3.00--5.76-----0.7287-0.72870.000.21970.00----0.00-169.22---191.76-------------3.320.00-------69.77------
Kairos Pharma Ltd0.00-2.74m18.75m----5.63-----0.2279-0.22790.000.25940.00-------92.10---264.70-------------2.610.0409-------72.57------
Neurosense Therapeutics Ltd0.00-7.51m19.28m16.00---------0.4392-0.43920.00-0.09430.00----0.00-154.72---470.03----------------------18.10------
Unity Biotechnology Inc0.00-19.05m19.71m19.00--1.39-----1.14-1.140.000.83940.00----0.00-32.73-47.21-38.49-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Forte Biosciences Inc0.00-34.20m19.79m11.00--2.11-----20.00-20.000.006.420.00----0.00-103.90-72.06-137.40-82.27-------491,850.00----0.00-------126.79---46.29--
Goldenwell Biotech Inc940.00-137.11k19.80m----5,169.71--21,063.83-0.0014-0.00140.000010.000040.00480.0031-----69.82---70.29--42.55---14,586.17--21.43--0.00---95.10--88.13------
Ibio Inc175.00k-14.36m20.01m16.00--1.07--114.35-3.97-6.650.03072.060.0056----10,937.50-46.17-27.69-75.53-33.13-----8,204.57-1,862.11----0.0736-----35.5247.31---26.66--
OpGen Inc1.96m-22.39m20.04m100.00------10.20-20.01-20.011.66-8.650.1553--6.09---176.99-87.95-15,455.17-127.653.1515.42-1,139.66-794.78---20.25----31.113.0212.38--40.20--
Spruce Biosciences Inc7.10m-39.43m20.24m22.00--0.3919--2.85-0.9598-0.95980.17281.250.0798----244,862.10-44.28-41.24-55.51-46.49-----555.23-1,774.39---121.120.0399-------3.77------
Pulmatrix Inc10.01m-9.66m20.53m22.00--1.88--2.05-2.64-2.642.742.990.4145--23.16454,772.70-40.00-46.91-44.64-58.12-----96.51-238.04----0.00--20.21116.6225.03--104.29--
Neurobo Pharmaceuticals Inc0.00-27.73m20.68m8.00--1.60-----4.77-4.770.001.500.00----0.00-114.20-95.57-159.68-135.64------------0.00------10.72--75.54--
Cocrystal Pharma Inc0.00-18.70m20.96m12.00--1.65-----1.84-1.840.001.250.00----0.00-76.57-50.94-83.17-52.77-------1,501.78----0.00------53.69--33.34--
Pieris Pharmaceuticals Inc1.35m-15.95m21.14m46.00--1.30--15.63-12.61-12.611.0612.320.0338--1.9129,391.30-39.93-28.41-68.21-39.69-----1,179.96-94.61----0.00--65.288.0326.25---36.82--
Data as of Jun 28 2024. Currency figures normalised to Goldenwell Biotech Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.